ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Diagnostic yield of familial pancreatic cancer screening and surveillance

Diagnostic yield of familial pancreatic cancer screening and surveillance
Study High-risk group Imaging tests Diagnostic yield*
Brentnall 1999; n = 14 FPC EUS + ERCP + CT 7/14 (50%)
Kimmey 2002; n = 46Δ FPC EUS; ERCP◊ 12/46 (26%)
Canto 2004; n = 38 FPC, PJS EUS; ERCP◊, EUS-FNA◊, CT◊ 2/38 (5.3%)
Canto 2006; n = 78 FPC, PJS EUS; CT◊, EUS-FNA◊, ERCP◊ 8/78 (10.2%)§
Poley 2009; n = 44 FPC, BRCA, PJS, CDKN2A, p53, hereditary pancreatitis EUS; CT◊, MRI◊ 10/44 (23%)
Langer 2009; n = 76 FPC, BRCA EUS + MRCP; EUS-FNA◊ 1/76 (1.3%)§
Verna 2010; n = 51 FPC, BRCA, CDKN2A EUS and/or MRCP 6/51 (12%)
Ludwig 2011; n = 109 FPC, BRCA MRCP; EUS◊, EUS-FNA◊ 9/109 (8.3%)§
Vasen 2011; n = 79 CDKN2A MRI/MRCP 14/79 (18%)
Al-Sukhni 2011; n = 262 FPC, BRCA, PJS, CDKN2A, hereditary pancreatitis MRI; CT◊, EUS◊, ERCP◊ 19/262 (7.3%)§
Schneider 2011¥; n = 72 FPC, BRCA, PALB2 EUS+MRCP 11/72 (15%)§
Canto 2012; n = 216 FPC, BRCA, PJS CT, MRI/MRCP, EUS; ERCP◊ 5/216 (2.3%) – 92/216 (42%)
Harinck 2015; n = 139 FPC, BRCA, PJS, CDKN2A MRI, EUS 11/139 (8%)§
Vasen 2016; n = 411 FPC, BRCA, PALB2, CDKN2A MRI, MRCP, EUS 32/411 (7.8%)§
Overbeek 2021; n = 366 FPC, CDKN2A, BRCA, PALB2, STK11/LKB1, TP53, ATM EUS and MRI/MRCP 10/165 (6%) in mutation carriers; 0/201 in FPC kindreds‡
FPC: familial pancreatic cancer; EUS: endoscopic ultrasound; ERCP: endoscopic retrograde cholangiopancreatography; CT: computed tomography; PJS: Peutz-Jeghers syndrome; EUS-FNA: endoscopic ultrasound-guided fine needle aspiration; BRCA: breast-related cancer; CDKN2A: cyclin-dependent kinase inhibitor 2A; MRI: magnetic resonance imaging; MRCP: magnetic resonance cholangiopancreatography; IPMN: intraductal papillary mucinous neoplasms.
* Yield is defined as the detection of any pathologically proven (pre)malignant lesion (≥PanIN2/IPMN and pancreatic adenocarcinoma) and lesions that are morphologically suspicious for branch-duct IPMNs.
¶ Includes only pathologically proven pancreatic neoplasms (histology or cytology).
Δ Continuation of Brentnall 1999, included 14 high-risk individuals from Brentnall 1999.
◊ Test performed only as an additional test for detected abnormalities.
§ Includes baseline and follow-up.
¥ Continuation of Langer 2009, includes high-risk individuals from this series.
‡ None of the cases were FPC kindreds. Estimated cumulative incidence of pancreatic ductal adenocarcinoma in mutation carriers was 6.5% at 5 years and 9.3% at 10 years.
Graphic 107901 Version 2.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟